Literature DB >> 23863158

Immune responses of macrophages and dendritic cells regulated by mTOR signalling.

Karl Katholnig1, Monika Linke, Ha Pham, Markus Hengstschläger, Thomas Weichhart.   

Abstract

The innate myeloid immune system is a complex network of cells that protect against disease by identifying and killing pathogens and tumour cells, but it is also implicated in homoeostatic mechanisms such as tissue remodelling and wound healing. Myeloid phagocytes such as monocytes, macrophages or dendritic cells are at the basis of controlling these immune responses in all tissues of the body. In the present review, we summarize recent studies demonstrating that mTOR [mammalian (or mechanistic) target of rapamycin] regulates innate immune reactions in macrophages and dendritic cells. The mTOR pathway serves as a decision maker to control the cellular response to pathogens and tumours by regulating the expression of inflammatory mediators such as cytokines, chemokines or interferons. In addition to various in vivo mouse models, kidney transplant patients under mTOR inhibitor therapy allowed the elucidation of important innate immune functions regulated by mTOR in humans. The role of the mTOR pathway in macrophages and dendritic cells enhances our understanding of the immune system and suggests new therapeutic avenues for the regulation of pro- versus anti-inflammatory mediators with potential relevance to cancer therapy, the design of novel adjuvants and the control of distinct infectious and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23863158      PMCID: PMC6322655          DOI: 10.1042/BST20130032

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  51 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages.

Authors:  Wuqiang Fan; Hidetaka Morinaga; Jane J Kim; Eunju Bae; Nathanael J Spann; Sven Heinz; Christopher K Glass; Jerrold M Olefsky
Journal:  EMBO J       Date:  2010-11-02       Impact factor: 11.598

3.  mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS.

Authors:  Heth R Turnquist; Jon Cardinal; Camila Macedo; Brian R Rosborough; Tina L Sumpter; David A Geller; Diana Metes; Angus W Thomson
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

4.  mTOR signaling pathway regulates the IL-12/IL-10 axis in Leishmania donovani infection.

Authors:  Satyanarayana Swamy Cheekatla; Amita Aggarwal; Sita Naik
Journal:  Med Microbiol Immunol       Date:  2011-05-13       Impact factor: 3.402

5.  Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy.

Authors:  S Brouard; I Puig-Pey; J-J Lozano; A Pallier; C Braud; M Giral; M Guillet; M C Londoño; F Oppenheimer; J M Campistol; J-P Soulillou; A Sanchez-Fueyo
Journal:  Am J Transplant       Date:  2010-12       Impact factor: 8.086

6.  The role of tuberous sclerosis complex 1 in regulating innate immunity.

Authors:  Hongjie Pan; Thomas F O'Brien; Ping Zhang; Xiao-Ping Zhong
Journal:  J Immunol       Date:  2012-03-12       Impact factor: 5.422

7.  Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: Implications for NO synthase 2 expression.

Authors:  Marta López-Peláez; Irene Soria-Castro; Lisardo Boscá; Margarita Fernández; Susana Alemany
Journal:  Eur J Immunol       Date:  2011-05-24       Impact factor: 5.532

8.  Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling.

Authors:  Taheri Sathaliyawala; William E O'Gorman; Melanie Greter; Milena Bogunovic; Vjollca Konjufca; Z Esther Hou; Garry P Nolan; Mark J Miller; Miriam Merad; Boris Reizis
Journal:  Immunity       Date:  2010-10-07       Impact factor: 31.745

9.  The phosphoproteome of toll-like receptor-activated macrophages.

Authors:  Gabriele Weintz; Jesper V Olsen; Katja Frühauf; Magdalena Niedzielska; Ido Amit; Jonathan Jantsch; Jörg Mages; Cornelie Frech; Lars Dölken; Matthias Mann; Roland Lang
Journal:  Mol Syst Biol       Date:  2010-06-08       Impact factor: 11.429

10.  Translational control of the innate immune response through IRF-7.

Authors:  Rodney Colina; Mauro Costa-Mattioli; Ryan J O Dowling; Maritza Jaramillo; Lee-Hwa Tai; Caroline J Breitbach; Yvan Martineau; Ola Larsson; Liwei Rong; Yuri V Svitkin; Andrew P Makrigiannis; John C Bell; Nahum Sonenberg
Journal:  Nature       Date:  2008-02-13       Impact factor: 49.962

View more
  27 in total

1.  Leishmania donovani Lipophosphoglycan Increases Macrophage-Dependent Chemotaxis of CXCR6-Expressing Cells via CXCL16 Induction.

Authors:  Visnu Chaparro; Louis-Philippe Leroux; Aude Zimmermann; Armando Jardim; Brent Johnston; Albert Descoteaux; Maritza Jaramillo
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

2.  Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis.

Authors:  Karl Katholnig; Birgit Schütz; Stephanie D Fritsch; David Schörghofer; Monika Linke; Nyamdelger Sukhbaatar; Julia M Matschinger; Daniela Unterleuthner; Martin Hirtl; Michaela Lang; Merima Herac; Andreas Spittler; Andreas Bergthaler; Gernot Schabbauer; Michael Bergmann; Helmut Dolznig; Markus Hengstschläger; Mark A Magnuson; Mario Mikula; Thomas Weichhart
Journal:  JCI Insight       Date:  2019-10-17

3.  Reduction of infection by inhibiting mTOR pathway is associated with reversed repression of type I interferon by porcine reproductive and respiratory syndrome virus.

Authors:  Qinfang Liu; Laura C Miller; Frank Blecha; Yongming Sang
Journal:  J Gen Virol       Date:  2017-06-14       Impact factor: 3.891

4.  Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus.

Authors:  Yingjuan Lu; Nikki Parker; Paul J Kleindl; Vicky A Cross; Kristin Wollak; Elaine Westrick; Torian W Stinnette; Mark A Gehrke; Kevin Wang; Hari Krishna R Santhapuram; Fei You; Spencer J Hahn; Jeremy F Vaughn; Patrick J Klein; Iontcho R Vlahov; Philip S Low; Christopher P Leamon
Journal:  Mol Med       Date:  2015-07-08       Impact factor: 6.354

5.  An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.

Authors:  Kameswaran Ravichandran; Iram Zafar; Abdullah Ozkok; Charles L Edelstein
Journal:  Nephrol Dial Transplant       Date:  2014-09-19       Impact factor: 5.992

Review 6.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 7.  Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.

Authors:  Adrian M Eiden; Shuling Zhang; Joy M Gary; John K Simmons; Beverly A Mock
Journal:  Clin Cancer Res       Date:  2015-11-25       Impact factor: 12.531

Review 8.  mTORC1 and mTORC2 as regulators of cell metabolism in immunity.

Authors:  Monika Linke; Stephanie Deborah Fritsch; Nyamdelger Sukhbaatar; Markus Hengstschläger; Thomas Weichhart
Journal:  FEBS Lett       Date:  2017-06-23       Impact factor: 4.124

9.  Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models.

Authors:  Sevdican Üstün; Caroline Lassnig; Andrea Preitschopf; Mario Mikula; Mathias Müller; Markus Hengstschläger; Thomas Weichhart
Journal:  Transpl Immunol       Date:  2015-06-11       Impact factor: 1.708

10.  TNFR2/14-3-3ε signaling complex instructs macrophage plasticity in inflammation and autoimmunity.

Authors:  Wenyu Fu; Wenhuo Hu; Young-Su Yi; Aubryanna Hettinghouse; Guodong Sun; Yufei Bi; Wenjun He; Lei Zhang; Guanmin Gao; Jody Liu; Kazuhito Toyo-Oka; Guozhi Xiao; David B Solit; Png Loke; Chuan-Ju Liu
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.